Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: james who wrote (1314)	12/1/1997 11:16:00 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 4676

To Bob, James, Amateur, and others: Bob: ISIP and GERN do not have much of similarity when the problem is reactivating telomerase activity. When problem is telomerase activity, cancer therapy, than antisense approach may have good chance for success. From preliminary Antisense 98 program (San Diego, Feb. 98) I learned that one company will present data from in-vitro and in-vivo (animal) studies of the antisense against telomerase activity in cancer model. I do not know who is this company. IMO, at this time, collaboration between ISIP and GERN is not likely. However, GERN noted in their SEC 10K file that Isis has patent application for telomerase antisense. Nebraska University received patent for this antisense type. GERN is expecting patent issuance. James: You links are not completed. I do not know which company alliance you are looking for! Also, IMO, article in Cell is bad example (not adequate axperiments) for determining telomerase activity rule in cancer cells proliferation/grow. I do think that telomerase activity inhibitor will be good approach for cancer therapy. Problem is in complex enzyme mechanism (combination of the protein/RNA translation) and it will be hard to develop specific and potent inhibitor. Antisense may have better chance, at this time??? Amateur: Hybridon antisense modification (their three patents) is based on -O'-Me RNA modification at each end with keeping P=S DNA at middle part or different -O'-X modification on middle part (GAP) with P=S DNA at each end. This is opposite to GAPmers Isis modification ( -O'-EtOMe P=O RNA at each end with P=S DNA at midle). Any idea, from antisense 97, or data for property of this Hybridon modification? I am puzzled what is holding patent issuance (to Isis) on GAPmers antisense modification? mz